Placebo News and Research

RSS

UC enrolling patients for clinical trial of novel PTSD treatments

About 8% of Americans will experience post-traumatic stress disorder at some point in their lives, but there are still few effective options to treat the condition.

28 Jun 2022

Phase 1 clinical trial of new influenza vaccine begins at NIH Clinical Center in Bethesda

A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland.

28 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

There remains no evidence to support the use of ivermectin for treating or preventing COVID-19 infection, state the authors of an updated Cochrane Review, which now contains 11 trials across 3409 people.

24 Jun 2022

COVID-19 rebound risks similar for Paxlovid and Molnupiravir

In a recent article posted to the medRxiv* preprint server, investigators in the United States illustrated that rebound of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can occur in some patients following molnupiravir and Paxlovid SARS-CoV-2 therapy.

23 Jun 2022

The effect of immunization with bivalent oral poliovirus vaccine on the incidence of COVID-19

Researchers evaluated the impact of the OPV on the incidence of COVID-19.

23 Jun 2022

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

In a recent study published in the Cochrane Library, researchers searched multiple databases to identify randomized controlled trials (RCTs) that evaluated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralizing monoclonal antibodies (mAbs).

23 Jun 2022

Real-world study shows Paxlovid associated with lower hospitalization rates

In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).

20 Jun 2022

Fecal microbiota transplant shows durable effect in treating irritable bowel syndrome

A new study discusses the efficacy of fecal transplant in patients with IBS three years after the procedure was performed.

16 Jun 2022

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

Varenicline improves quit rates among African American daily smokers

African Americans have been underrepresented in tobacco treatment research, including the clinical trials that led to the 2006 FDA approval of varenicline, the leading pharmacological treatment for smoking cessation commonly known by the brand name Chantix.

14 Jun 2022

Increasing growth hormone levels can improve liver health in patients with NAFLD

Growth hormone improves liver health in patients with nonalcoholic fatty liver disease (NAFLD) by reducing liver fat and inflammation, according to a new study presented Tuesday, June 14 at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

14 Jun 2022

Fezolinetant reduces the frequency and severity of menopausal hot flashes, study finds

Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society's annual meeting in Atlanta, Ga.

13 Jun 2022

The physiological relevance and effects of probable in vivo transformation of CBD to delta9-THC in humans

Researchers reviewed studies on the probable conversion of orally administered cannabidiol (CBD) to delta9-tetrahydrocannabinol (delta9-THC or THC) in humans.

10 Jun 2022

Study finds Moderna COVID vaccine efficacy peaks at 94% after 120 days

A recent research letter posted to the JAMA Network Open assessed the durability of immunity conferred by the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA)-1273 vaccine.

10 Jun 2022

The effectiveness of non-pharmacological treatments for post-viral syndromes and long COVID

A recent systematic review investigated the effectiveness of non-pharmacologic interventions for post-viral syndromes, including the post-COVID-19 syndrome.

9 Jun 2022

Analysis finds little proof that testosterone treatment increases the risk of cardiovascular events

Testosterone replacement therapy appears safe in the short-to-medium term to treat a condition caused by deficiency of the male sex hormone, according to the most comprehensive analysis of the treatment to date, published in The Lancet Healthy Longevity journal.

9 Jun 2022

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

8 Jun 2022

Targeted dietary measures can reduce the symptom burden in allergic reactions, trial shows

Micronutrient deficiencies can promote inflammation and render the immune system particularly sensitive to allergenic substances.

8 Jun 2022

Placebo News and Research

UC enrolling patients for clinical trial of novel PTSD treatments

Phase 1 clinical trial of new influenza vaccine begins at NIH Clinical Center in Bethesda

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

COVID-19 rebound risks similar for Paxlovid and Molnupiravir

The effect of immunization with bivalent oral poliovirus vaccine on the incidence of COVID-19

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

Real-world study shows Paxlovid associated with lower hospitalization rates

Fecal microbiota transplant shows durable effect in treating irritable bowel syndrome

Combination of three technologies makes potential treatment effective against aggressive brain tumor

Varenicline improves quit rates among African American daily smokers

Increasing growth hormone levels can improve liver health in patients with NAFLD

Fezolinetant reduces the frequency and severity of menopausal hot flashes, study finds

The physiological relevance and effects of probable in vivo transformation of CBD to delta9-THC in humans

Study finds Moderna COVID vaccine efficacy peaks at 94% after 120 days

The effectiveness of non-pharmacological treatments for post-viral syndromes and long COVID

Analysis finds little proof that testosterone treatment increases the risk of cardiovascular events

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

Targeted dietary measures can reduce the symptom burden in allergic reactions, trial shows

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News